CCEA approves mission for development of bio-pharmaceuticals

Image
IANS New Delhi
Last Updated : May 17 2017 | 9:07 PM IST

The Cabinet Committee on Economic Affairs (CCEA) on Wednesday approved a collaborative mission between industry and academia for accelerating research for early development of bio pharmaceuticals.

The programme entails an investment of Rs 1,500 crore by the central government over a period of five years. Half the funding will be arranged through the World Bank loan.

Besides, the 'Innovate in India empowering biotech entrepreneurs and accelerating inclusive innovation' mission will also work on establishment of shared infrastructure and facilities.

"The mission will provide a holistic and integrated approach to strengthen and support the entire product development value chain for accelerating the research leads to product development," said an official statement.

"This will help not only in immediate product development addressing public health needs, but will also help to create an ecosystem which will facilitate development of a continuous pipeline of products," it said.

The programme would focus on development of specific products such as vaccines, bio therapeutics, medical devices and diagnostics.

It would also focus on building and strengthening domain specific knowledge and management skills; creating and enhancing technology transfer capabilities in public and private sector.

The Mission will be implemented by Biotechnology Industry Research Assistance Council (BIRAC) -- a Public Sector Undertaking of the Department of Biotechnology (DBT).

The total project cost to be funded by central government is Rs 1,500 crore for five years,

For the implementation, a Programme Management Unit would be set up at BIRAC, which will work as an operational and functional arm that oversees and monitors program implementation and progress.

--IANS

rup/pgh/vt

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 17 2017 | 8:56 PM IST

Next Story